 SAN FRANCISCO, Sept. 08, 2021 GLOBE NEWSWIRE -- 89bio, Inc. Nasdaq: ETNB, a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Companys Management will participate in the H.C. Wainwright 23rd Annual Global Investment Conference to be held September 13-15, 2021. 